Related Experiment Videos
Topically applied levobunolol does not cause changes in the corneal endothelium
R Fusco1, A Del Prete, A Gravina
12nd Medicine School Naples, 2nd Eye Clinic Prof. Mario D'Esposito, Napoli, Italy.
Documenta Ophthalmologica. Advances in Ophthalmology
|January 1, 1990
Summary
Topical levobunolol treatment did not affect corneal endothelial cell count or morphology in ocular hypertension patients. This study confirms the drug
Area of Science:
- Ophthalmology
- Corneal Science
- Pharmacology
Background:
- Ocular hypertension requires treatment to prevent glaucoma.
- Corneal endothelial cells are vital for maintaining corneal clarity.
- Understanding drug effects on the cornea is crucial for patient safety.
Purpose of the Study:
- To investigate the impact of topical levobunolol on corneal endothelial cell characteristics.
- To assess the safety of levobunolol concerning endothelial cell integrity.
Main Methods:
- Corneal endothelium examination in ten ocular hypertension patients.
- Treatment with topical levobunolol for four months.
- Comparison with untreated fellow eyes as controls.
- Cell counting and morphological assessment using specialized equipment.
Main Results:
- Levobunolol therapy did not alter the number of corneal endothelial cells.
- The morphology of corneal endothelial cells remained unaffected by the drug.
- No adverse effects on the corneal endothelium were observed.
Conclusions:
- Topical levobunolol appears safe for the corneal endothelium.
- The drug does not negatively impact endothelial cell count or structure.
- Levobunolol can be considered a safe treatment option for ocular hypertension regarding corneal health.